New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 3, 2014
06:28 EDTREGN, CELGAtopic dermatitis could bring upside to Regeneron, Celgene, says Citigroup
Citigroup believes Regeneron's (REGN) dupilumab and Celgene's (CELG) Otezla for atopic dermatitis are being overlooked by investors and could provide upside for both names. Citi believes both drugs have good efficacy but adds that dupilumab is more advanced. The firm has a Buy rating on both stocks.
News For REGN;CELG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
February 20, 2015
09:38 EDTCELGActive equity options trading on open
Subscribe for More Information
07:08 EDTREGNAmerican Academy of Allergy, Asthma and Immunology to hold annual meeting
2015 Annual Meeting of AAAAI is being held in Houston, Texas on February 20-24.
05:27 EDTCELGCelgene Revlimid approved by EC
Subscribe for More Information
February 19, 2015
16:28 EDTREGNOn The Fly: Closing Wrap
Subscribe for More Information
15:58 EDTREGNRegeneron downgraded to Neutral from Buy at Roth Capital
Subscribe for More Information
10:00 EDTREGNRegeneron Praluent launch costs a concern, says Piper Jaffray
Subscribe for More Information
09:01 EDTREGNData to accelerate growth of Regeneron's Eylea, says Bernstein
Subscribe for More Information
07:28 EDTREGNRegeneron data better than expected, says RBC Capital
RBC Capital believes that Protocol-T results for Regneron's (REGN) Eylea were better than expected. The firm says that Eylea improved the vision of all patients more than Roche's treatments,and was much better than Roche's drugs in treating patients with moderate or worse vision loss. The firm keeps a $490 price target and Outperform rating on Regeneron.
06:56 EDTREGNData support Regeneron drug over competition, says Deutsche Bank
Subscribe for More Information
06:45 EDTREGNStudy shows Roche's treatments equal to Eylea in most cases, NY Times says
Subscribe for More Information
February 18, 2015
17:23 EDTREGNRegeneron reports positive results for Eylea injection in diabetic macular edema
Subscribe for More Information
16:00 EDTCELGOptions Update; February 18, 2015
Subscribe for More Information
10:05 EDTCELGOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:38 EDTCELGCelgene reports FDA expands indication for Revlimid combo
Subscribe for More Information
09:37 EDTCELGOption volume leaders on open
Option volume leaders: AAPL TSLA TWTR CELG APO NFLX AXP APA LNKD C GILD according to Track Data.
06:47 EDTCELGCelgene initiated with a Buy at Canaccord
Target $156.
03:20 EDTREGNOn The Fly: Analyst Initiation Summary
Subscribe for More Information
February 17, 2015
10:01 EDTREGNCVS says PCSK9 inhibitors could cost system $150B annually
Subscribe for More Information
10:00 EDTREGNOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Box, Inc. (BOX) initiated with a Hold at Canaccord... Euronav NV (EURN) initiated with an Overweight at Morgan Stanley... GoPro (GPRO) initiated with an Outperform at Northland... M/A-COM (MTSI) initiated with a Neutral at BofA/Merrill... Macy's (M) initiated with an Underweight at Barclays... NetSuite (N) initiated with an Underperform at Exane BNP Paribas... Omega Healthcare (OHI) initiated with a Neutral at BofA/Merrill... Pandora (P) initiated with a Neutral at Macquarie... Pattern Energy (PEGI) coverage resumed with an Outperform at BMO Capital... Regeneron (REGN) initiated with an Outperform at Bernstein... Trovagene (TROV) initiated with an Overweight at Piper Jaffray... Vista Outdoor (VSTO) initiated with a Market Perform at Cowen.
06:35 EDTREGNRegeneron initiated with an Outperform at Bernstein
Target $475.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use